Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Renal Cell 13Prostatic Neoplasms 8Urinary Bladder Neoplasms 6Kidney Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Neoplasm Metastasis 3Colonic Neoplasms 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Neoplasms 2Lung Neoplasms 2Hereditary leiomyomatosis and renal cell cancer 2Glioma 2Esthesioneuroblastoma, Olfactory 2Ependymoma 2Wilms Tumor 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thrombocytosis 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Papillary renal cell carcinoma, sporadic 1Osteosarcoma 1Oligodendroglioma 1

Interventions

pembrolizumab 75Nivolumab 46Cyclophosphamide 25aldesleukin 23fludarabine 16atezolizumab 15Ipilimumab 15Interleukin-2 14Radiosurgery 13Paclitaxel 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Carboplatin 11fludarabine phosphate 9Docetaxel 9durvalumab 8Cisplatin 8cemiplimab 7Bevacizumab 7Radiotherapy 6Gemcitabine 6Biopsy 6spartalizumab 5avelumab 5Pemetrexed 5Oxaliplatin 5Immune Checkpoint Inhibitors 5Filgrastim 5Cryosurgery 5Blood Specimen Collection 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Erlotinib Hydrochloride × Genitourinary × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡